Table 1.
Prerandomization Characteristics
Variable | CA21 (n=10) | CA100 (n=10) | P Value |
---|---|---|---|
Baseline | |||
Weight, kg | 10.4 | 10.3 | 0.78 |
Body temperature, °C | 37.4 (37.1–37.7) | 37.6 (37.3–37.7) | 0.54 |
Heart rate, bpm | 138 (9.4) | 120 (8.9) | 0.18 |
Systolic aortic BP, mm Hg | 76.2 (3.2) | 76.9 (3.4) | 0.56 |
Diastolic aortic BP, mm Hg | 53.9 (51.1–56.3) | 51.1 (50.4–57.9) | 0.65 |
Pao 2, mm Hg | 114 (108–119) | 115 (108–118) | 0.76 |
SpO2, % | 96.6 (0.44) | 96.6 (0.48) | 0.95 |
Paco 2, mm Hg | 114 (108–119) | 115 (108–118) | 0.76 |
ETCO2, mm Hg | 39.9 (38.5–43.5) | 39.1 (38.2–40.4) | 0.29 |
Brain temperature, °C | 36.9 (36.4–37.0) | 37.0 (36.4–37.1) | 0.74 |
Intracranial pressure, mm Hg | 13.1 (2.3) | 14.1 (1.3) | 0.61 |
Asphyxia | |||
Body temperature, °C | 37.4 (37.1–37.8) | 37.6 (37.5–37.7) | 0.40 |
Heart rate, bpm | 108.7 (16.5) | 93.5 (16.9) | 0.53 |
Systolic aortic BP, mm Hg | 38.2 (7.9) | 41.3 (10.7) | 0.82 |
Diastolic aortic BP, mm Hg | 23.6 (3.6) | 21.4 (4.0) | 0.69 |
Mean arterial BP, mm Hg | 28.5 (4.9) | 28.0 (6.2) | 0.95 |
Achieved pulseless electrical activity, n (%) | 4 (40) | 5 (50) | 0.67 |
Pao 2, mm Hg | 7.8 (1.3) | 6.4 (1.9) | 0.55 |
SpO2, % | 15.5 (7.4) | 14.7 (5.9) | 0.94 |
Paco 2, mm Hg | 62.2 (4.5) | 60.8 (4.6) | 0.83 |
ETCO2, mm Hg | 0.94 (0.22–1.7) | 0.71 (0.21–2.88) | 0.88 |
Brain temperature, °C | 37.0 (36.0–37.3) | 37.1 (36.7–37.2) | 0.82 |
Intracranial pressure, mm Hg | 11.9 (1.9) | 13.8 (1.2) | 0.38 |
Brain tissue oxygen tension, % baseline | 8.2 (3.9) | 9.6 (3.3) | 0.80 |
Cerebral blood flow, % baseline | 27.3 (9.8) | 22.7 (7.7) | 0.72 |
Comparison between groups at baseline (mean values during 2 minutes preceding start of asphyxia) and during asphyxia, before induction of ventricular fibrillation and randomization to treatment group. Student t test is used for normally distributed data. Wilcoxon rank‐sum test is used for nonnormally distributed data. Values are mean (SEM) or median (interquartile range). BP indicates blood pressure; bpm, beats per minute; CA21, cardiac arrest (CA) with cardiopulmonary resuscitation (CPR) in 0.21 fraction of inspired oxygen (FiO2); CA100, CA with CPR in 1.0 fraction of FiO2; ETCO2, end‐tidal carbon dioxide; and SpO2, peripheral capillary oxygen saturation.